Carregant...
Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO‐2 randomized clinical study
AIMS: Glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors treat type 2 diabetes through incretin‐signaling pathways. This study compared the efficacy and safety of the glucagon‐like peptide‐1 receptor agonist exenatide once‐weekly (Miglyol) suspension for autoinjection (Q...
Guardat en:
| Publicat a: | Diabetes Obes Metab |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Publishing Ltd
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5485171/ https://ncbi.nlm.nih.gov/pubmed/28205322 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12908 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|